Evaluation of neck and body metastases to nodes with ferumoxtran 10-enhanced MR imaging: Phase III safety and efficacy study

Radiology

Volumn 228, Issue 3, 2003, Pages 777-788

  Anzai, Yoshimi ^a   Piccoli, Catherine W ^a   Outwater, Eric K ^a   Stanford, William ^a   Bluemke, David A ^a   Nurenberg, Pamela ^a   Saini, Sanjay ^a   Maravilla, Kenneth R ^a   Feldman, David E ^a   Schmiedl, Udo P ^a   Brunberg, James A ^a   Francis, Isaac R ^a   Harms, Steven E ^a   Som, Peter M ^a   Tempany, Clare M ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Contrast media; Iron; Lymphatic system, MR; Lymphatic system, neoplasms; Magnetic resonance (MR), contrast enhancement

Indexed keywords

FERUMOXTRAN 10; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE;

ADULT; AGED; ARTICLE; BACKACHE; CLINICAL TRIAL; CONTRAST ENHANCEMENT; CONTRAST SENSITIVITY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEADACHE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NECK METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 3 CLINICAL TRIAL; RECEIVER OPERATING CHARACTERISTIC; RELIABILITY; THORAX PAIN; URTICARIA; VASODILATATION;

ADOLESCENT; ADULT; CONTRAST MEDIA; HUMANS; IRON; LYMPH NODES; LYMPHATIC METASTASIS; MAGNETIC RESONANCE IMAGING; MULTICENTER STUDIES; NEOPLASM STAGING; OXIDES; ROC CURVE; SAFETY; SENSITIVITY AND SPECIFICITY;

EID: 0042932291     PISSN: 00338419     EISSN: None     Source Type: Journal    
DOI: 10.1148/radiol.2283020872     Document Type: Article

References (32)

1. Varallyay P, Nesbit G, Muldoon LL, et al. Comparison of two superparamagnetic viral-sized iron oxide particles ferumoxides and ferumoxtran 10 with a gadolinium chelate in imaging intracranial tumors. AJNR Am J Neuroradiol 2002; 23:510-519.
2. Zimmer C, Weissleder R, Poss K, Bogdanova A, Wright SC, Enochs WS. MR imaging of phagocytosis in experimental gliomas. Radiology 1995; 197:533-538.
3. Moore A, Marcecos E, Bogdanow AJ, Weissleder R. Tumoral distribution of long-circulating dextran-coated iron oxide nanoparticles in a rodent model. Radiology 2000; 214:568-574.
4. Weissleder R, Heautot JF, Schaffer BK, et al. MR lymphography: study of a high-efficiency lymphotrophic agent. Radiology 1994; 191:225-230.
5. Weissleder R, Elizondo G, Josephson L, et al. Experimental lymph node metastases: enhanced detection with MR lymphography. Radiology 1989; 171:835-839.
6. Weissleder R, Elizondo G, Wittenberg J, Lee AS, Josephson L, Brady TJ. Ultrasmall superparamagnetic iron oxide: an intravenous contrast agent for assessing lymph nodes with MR imaging. Radiology 1990; 175:494-498.
7. Lee AS, Weissleder R, Brady TJ, Wittenberg J. Lymph nodes: microstructural anatomy at MR imaging. Radiology 1991; 178:519-522.
8. Guimaraes R, Clement O, Bittoun J, Carnot F, Frija G. MR lymphography with superparamagnetic iron nanoparticles in rats: pathologic basis for contrast enhancement. AJR Am J Roentgenol 1994; 162:201-207.
9. Hamm B, Taupitz M, Hussmann P, Wagner S, Wolf KJ. MR lymphography with iron oxide particles: dose-response studies and pulse sequence optimization in rabbits. AJR Am J Roentgenol 1992; 158:183-190.
10. Vassallo P, Matei C, Heston WD, McLachlan SJ, Koutcher JA, Castellino RA. Characterization of reactive versus tumor-bearing lymph nodes with interstitial magnetic resonance lymphography in an animal model. Invest Radiol 1995; 30:706-711.
11. Muhler A, Zhang X, Wang H, Lawaczeck, R, Weinmann HJ. Investigation of mechanisms influencing the accumulation of ultrasmall superparamagnetic iron oxide particles in lymph nodes. Invest Radiol 1995; 30:98-103.
12. Rety F, Clement O, Siauve N, et al. MR lymphography using iron oxide nanoparticles in rats: pharmacokinetics in the lymphatic system after intravenous injection. J Magn Reson Imaging 2000; 12:734-739.
13. Tanoura T, Bernas M, Darkazanli A, et al. MR lymphography with iron oxide compound AMI-227: studies in ferrets with filariasis. AJR Am J Roentgenol 1992; 159:875-881.
14. Hudgins PA, Anzai Y, Morris MR, Lucas MA. Ferumoxtran-10, a superparamagnetic iron oxide as a magnetic resonance enhancement agent for imaging lymph nodes: a phase 2 dose study. AJNR Am J Neuroradiol. 2002 Apr;23(4):649-656.
15. Bengele HH, Palmacci S, Rogers J, Jung CW, Crenshaw J, Josephson L. Biodistribution of an ultrasmall superparamagnetic iron oxide colloid, BMS 180549, by different routes of administration. Magn Reson Imaging 1994; 12:433-442.
16. McLachlan SJ, Morris MR, Lucas MA, et al. Phase I clinical evaluation of a new iron oxide MR contrast agent. J Magn Reson Imaging 1994; 4:301-307.
17. Anzai Y, Blackwell KE, Hirschowitz SL, et al. Initial clinical experience with dextran-coated superparamagnetic iron oxide for detection of lymph node metastases in patients with head and neck cancer. Radiology 1994; 192:709-715.
18. Bellin MF, Roy C, Kinkel K, et al. Lymph node metastases: safety and effectiveness of MR imaging with ultrasmall superparamagnetic iron oxide particles - initial clinical experience. Radiology 1998; 207:799-808.
19. Harisinghani MG, Saini S, Slater GJ, Schnall MD, Rifkin MD. MR imaging of pelvic lymph nodes in primary pelvic carcinoma with ultrasmall superparamagnetic iron oxide (Combidex): preliminary observations. J Magn Reson Imaging 1997; 7:161-163.
20. Harisinghani MG, Saini S, Weissleder R, et al. MR lymphangiography using ultrasmall superparamagnetic iron oxide in patients with primary abdominal and pelvic malignancies: radiographic-pathologic correlation. AJR Am J Roentgenol 1999; 172:1347-1351.
21. Hoffman HT, Quets J, Toshiaki T, et al. Functional magnetic resonance imaging using iron oxide particles in characterizing head and neck adenopathy. Laryngoscope 2000; 110:1425-1430.
22. Nguyen BC, Stanford W, Thompson BH, et al. Multicenter clinical trial of ultrasmall superparamagnetic iron oxide in the evaluation of mediastinal lymph nodes in patients with primary lung carcinoma. J Magn Reson Imaging 1999; 10:468-473.
23. Pannu HK, Wang KP, Borman TL, Bluemke DA. MR imaging of mediastinal lymph nodes: evaluation using a superparamagnetic contrast agent. J Magn Reson Imaging 2000; 12:899-904.
24. Byers RM, El-Naggar AK, Lee YY, et al. Can we detect or predict the presence of occult nodal metastases in patients with squamous carcinoma of the oral tongue? Head Neck 1998; 20:138-144.
25. Hosal AS, Carrau RL, Johnson JT, Myers EN. Selective neck dissection in the management of the clinically node-negative neck. Laryngoscope 2000; 110:2037-2040.
26. Johnson JT. Selective neck dissection in patients with squamous cell carcinoma of the upper respiratory and digestive tracts: a lack of adequate data. Arch Otolaryngol Head Neck Surg 1998; 124:353.
27. van den Brekel MW, Castelijns JA, Snow GB. The size of lymph nodes in the neck on sonograms as a radiologic criterion for metastasis: how reliable is it? AJNR Am J Neuroradiol 1998; 19:695-700.
28. Dillon WP. Cervical nodal metastases: another look at size criteria. AJNR Am J Neuroradiol 1998; 19:796-797.
29. Curtin HD, Ishwaran H, Mancuso AA, Dalley RW, Caudry DJ, McNeil BJ. Comparison of CT and MR imaging in staging of neck metastases. Radiology 1998; 207:123-130.
30. Sigal R, Vogl T, Casselman J, et al. Lymph node metastases from head and neck squamous cell carcinoma: MR imaging with ultrasmall superparamagnetic iron oxide particles (Sinerem MR) results of a phase-III multicenter clinical trial. Eur Radiol 2002; 12:1104-1113.
31. Sharma R, Saini S, Ros PR, et al. Safety profile of ultrasmall superparamagnetic iron oxide ferumoxtran 10: phase II clinical trial data. J Magn Reson Imaging 1999; 9:291-294.
32. Ros PR, Freeny PC, Harms SE, et al. Hepatic MR imaging with ferumoxides: a multicenter clinical trial of the safety and efficacy in the detection of focal hepatic lesions. Radiology 1995; 196:481-488.